Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma

Fig. 3

Laboratory changes and treatment response. (A) tumor responses in each cohort; (B) Median change AFP from Before and after treatment in patients with baseline AFP > 7 ng/mL (n = 62); (C) Changes in liver function indicators of each patient before and after treatment. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease; DCR (CR + PR + SD), disease control rate; ORR (CR + PR), objective response rate; AFP, a-fetoprotein; ALT, alanine aminotransferase

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us